This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Find out more here.

eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
New eMC coming June 2013...

International Medication Systems (UK) Ltd

208 Bath Road, Slough, Berkshire, SL1 3WE
Telephone: +44 (0)1753 534 655
Medical Information Direct Line: +44 (0)1753 447 690
Medical Information e-mail: medicalinformationuk@ucb.com
Customer Care direct line: +44 (0)800 953 0183
Medical Information Fax: +44 (0)1753 447 647

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 22/07/2013
SPC Epinephrine (Adrenaline) Injection 1:10,000


Go to top of the page
1. Name of the medicinal product

Adrenaline (Epinephrine) 1:10,000 Sterile Solution Minijet®.


Go to top of the page
2. Qualitative and quantitative composition

Adrenaline (Epinephrine) USP 0.1mg per ml.


Go to top of the page
3. Pharmaceutical form

Sterile aqueous solution for parenteral administration.


Go to top of the page
4. Clinical particulars

Go to top of the page
4.1 Therapeutic indications

Adjunctive use in the management of cardiac arrest.

In cardiopulmonary resuscitation. Intracardiac puncture and intramyocardial injection of adrenaline may be effective when external cardiac compression and attempts to restore the circulation by electrical defibrillation or use of a pacemaker fail.


Go to top of the page
4.2 Posology and method of administration

Ventricular fibrillation (pulseless ventricular tachycardia)

Adults:

Intravenous injection: 10ml (1mg) by intravenous injection repeated every 3-5 minutes as necessary.

Endotracheal: 20-30ml (2-3mg) via an endotracheal tube, repeated as necessary.

Intracardiac injection: 1 to 10ml (0.1 to 1mg), direct into the atrium of the heart.

Intracardiac injection should only be considered if there is no other access available. It should be undertaken by personnel trained in the technique.

Children:

Intravenous injection: Initially 0.1ml/kg body weight (10mcg/kg); e.g. 2kg infant would receive 0.2ml of Adrenaline 1:10,000. Subsequent doses should be 1ml/kg (100mcg/kg).

Intraosseous: 0.1ml/kg body weight (10mcg/kg).

Endotracheal: A dose has not been established; 10 times the intravenous dose may be appropriate.

Asystole

Adults:

Intravenous: 10ml (1mg) by intravenous injection repeated every 3-5 minutes as necessary. If there is no response after three cycles, consider injections of adrenaline 5mg.

Endotracheal: 20-30 ml (2-3mg) via an endotracheal tube, repeated as necessary.

Children:

Intravenous: 0.1ml/kg initially (10mcg/kg). If no response give 1ml/kg (100mcg/kg). After 3 cycles consider alkalising or antiarrhytmic agents.

Intraosseus: 0.1 ml/kg initially (10mcg/kg). If no response give 1ml/kg (100mcg/kg). After 3 cycles consider alkalising or antiarrhythmic agents.

Electromechanical Dissociation (EMD)

Adults:

Intravenous: 10ml (1mg) by intravenous injection repeated every 3-5 minutes as necessary. If normal rhythm does not return after standard measures, consider adrenaline 5mg intravenous.

Children:

Intravenous: 0.1ml/kg initially (10mcg/kg) every 3 minutes, until underlying cause identified. Subsequent doses should be 1ml/kg (100mcg/kg).


Go to top of the page
4.3 Contraindications

Contraindications are relative as this product is intended for use in life-threatening emergencies.

Other than in the emergency situation, the following contraindications should be considered: hyperthyroidism, hypertension, ischaemic heart disease, diabetes mellitus. closed angle glaucoma and hypersensitivity to sympathomimetic amines.


Go to top of the page
4.4 Special warnings and precautions for use

These special warnings and precautions are relative as this product is intended for use in life-threatening situations.

Administer slowly with caution to elderly patients and to patients with ischaemic heart disease, hypertension, diabetes mellitus, hyperthyroidism or psychoneurosis. Use with extreme caution in patients with long-standing bronchial asthma and emphysema who have developed degenerative heart disease. Anginal pain may be induced when coronary insufficiency is present.

Use with caution in patients with pre-existing cardiac arrhythmias. Tissue necrosis at injection site may arise if this product is administered to an inappropriate injection site such as digits or buttocks.

Administer with caution: In patients suffering from autonomic dysreflexia (hyperreflexia), particularly in spinal cord injury (e.g., tetraplegics). Patients with hypersensitivity to sulfites and patients with prostatic hypertrophy or urination difficulty.

Endotracheal administration of adrenaline can contaminate the colorimeter carbon dioxide detector and lead to its false positive colour change (fixed yellow discoloration).

This medicinal product contains 2.7 mg per ml sodium. To be taken into consideration by patients on a controlled sodium diet.

This medicinal product contains sodium bisulfite which may rarely cause severe hypersensitivity reactions and bronchospasm.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

The effects of adrenaline may be potentiated by tricyclic antidepressants. Volatile liquid anaesthetics such as halothane increase the risk of adrenaline-induced ventricular arrhythmias and acute pulmonary oedema if hypoxia is present. Severe hypertension and bradycardia may occur with non-selective beta-blocking drugs such as propranolol. Propranolol also inhibits the bronchodilator effect of adrenaline. The risk of cardiac arrhythmias is higher when adrenaline is given to patients receiving digoxin or quinidine. Adrenaline -induced hyperglycaemia may lead to loss of blood-sugar control in diabetic patients treated with hypoglycaemic agents.

The vasoconstrictor and pressor effects of adrenaline, mediated by its alpha-adrenergic action, may be enhanced by concomitant administration of drugs with similar effects, such as ergot alkaloids or oxytocin. Adrenaline specifically reverses the antihypertensive effects of adrenergic neurone blockers such as guanethidine with the risk of severe hypertension.

Concurrent use or use within 2 weeks of monoamine oxidase inhibitor increases risk of adverse events. Sympathomimetic drugs (e.g. isoproterenol) increase the risk of serious cardiac arrhythmias. Alpha blockers increase the risk of hypotension and tachycardia. Drugs which cause potassium loss (corticosteroids, potassium-depleting diuretic, aminophylline, theophylline) increases the risk of hypokalemia. Adrenaline increases the risk of cardiac adverse effects of levodopa.

Use of Entacapone may potentiate the chronotropic and arrhythmogenic effects of adrenaline.


Go to top of the page
4.6 Pregnancy and lactation

Adrenaline crosses the placenta. There is some evidence of a slightly increased incidence of congenital abnormalities. Injection of adrenaline may cause foetal tachycardia, cardiac irregularities, extrasystoles and louder heart sounds. In labour, adrenaline may delay the second stage. Adrenaline should only be used in pregnancy if the potential benefits outweigh the risks to the foetus.

Adrenaline is excreted in breast milk, but as pharmacologically active plasma concentrations are not achieved by the oral route, the use of adrenaline in breast feeding mothers is presumed to be safe.


Go to top of the page
4.7 Effects on ability to drive and use machines

Not applicable; this preparation is intended for use only in emergencies.


Go to top of the page
4.8 Undesirable effects

Psychiatric disorders

Anxiety

Restlessness

Nervous system disorders

Cerebral haemorrhage due to hypertension

Headache

Dizziness

Tremor

Cardiac disorders

The potentially severe adverse effects of adrenaline arise from its effect upon blood pressure and cardiac rhythm.

Ventricular fibrillation

Myocardial ischaemia

Myocardial infarction

Stress cardiomyopathy

Pulmonary oedema due to hypertension

Dyspnoea

Palpitations

Tachycardia

Anginal pain

Vascular disorders

Bowel necrosis

Cold extremities

Renal and urinary disorders

Difficulty in micturition and urinary retention.

General disorders and administration site conditions

Pallor

Weakness

Biochemical effects include inhibition of insulin secretion, stimulation of growth hormone secretion, hyperglycaemia (even with low doses), involvement in the processes of gluconeogenesis, glycolysis, lipolysis and ketogenesis.


Go to top of the page
4.9 Overdose

Symptoms: cardiac arrhythmias leading to ventricular fibrillation and death; severe hypertension leading to pulmonary oedema and cerebral haemorrhage.

Treatment: combined alpha- and beta-adrenergic blocking agents such as labetalol may counteract the effects of adrenaline, or a beta-blocking agent may be used to treat any supraventricular arrhythmias and phentolamine to control the alpha-mediated effects on the peripheral circulation. Rapidly acting vasodilators such as nitrates and sodium nitroprusside may also be helpful.

Immediate resuscitation support must be available.


Go to top of the page
5. Pharmacological properties

Go to top of the page
5.1 Pharmacodynamic properties

Adrenaline is a direct-acting sympathomimetic agent exerting its effect on alpha- and beta-adrenoceptors. The overall effect of adrenaline depends on the dose used, and may be complicated by the homeostatic reflex responses. In resuscitation procedures it is used to increase the efficacy of basic life support. It is a positive cardiac inotrope. Major effects are increased systolic blood pressure, reduced diastolic pressure (increased at higher doses), tachycardia, hyperglycaemia and hypokalaemia.


Go to top of the page
5.2 Pharmacokinetic properties

Adrenaline is rapid in onset and of short duration. After i.v. infusion the half-life is approximately 5-10 minutes. It is rapidly distributed to the heart, spleen, several glandular tissues and adrenergic nerves. It crosses the placenta and is excreted in breast milk. It is approximately 50% bound to plasma proteins.

Adrenaline is rapidly metabolised in the liver and tissues by oxidative deamination and O-methylation followed by reduction or by conjugation with glucuronic acid or sulphate. Up to 90% of the i.v. dose is excreted in the urine as metabolites.


Go to top of the page
5.3 Preclinical safety data

Not applicable since Adrenaline (Epinephrine) Injection has been used in clinical practice for many years and its effects in man are well known.


Go to top of the page
6. Pharmaceutical particulars

Go to top of the page
6.1 List of excipients

Citric Acid Monohydrate

Sodium Citrate (E331)

Sodium Chloride

Sodium Bisulphite (E222)

Dilute Hydrochloric Acid (for pH adjustment)

Water for Injection


Go to top of the page
6.2 Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

Adrenaline should not be mixed with sodium bicarbonate; the solution is oxidised to adrenochrome and then forms polymers.


Go to top of the page
6.3 Shelf life

3ml - 18 months.

10ml - 24 months.


Go to top of the page
6.4 Special precautions for storage

Do not store above 25°C. Keep container in outer carton in order to protect from light.


Go to top of the page
6.5 Nature and contents of container

The solution is contained in a USP type I glass vial with an elastomeric closure which meets all the relevant USP specifications. The product is available either as 3ml or 10ml. One minijet per carton.


Go to top of the page
6.6 Special precautions for disposal and other handling

The container is specially designed for use with the IMS Minijet injector. For single use only.

Any unused product or waste material should be disposed of in accordance with local requirements.


Go to top of the page
7. Marketing authorisation holder

International Medication Systems (UK) Ltd

208 Bath Road

Slough

Berkshire

SL1 3WE

UK


Go to top of the page
8. Marketing authorisation number(s)

PL 03265/0011R


Go to top of the page
9. Date of first authorisation/renewal of the authorisation

21 March 1991 / 29 November 2005


Go to top of the page
10. Date of revision of the text

July 2013

POM



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/4881/SPC/


Active Ingredients/Generics